The interactive effects of ketamine and nicotine on human cerebral blood flow

被引:22
作者
Rowland, Laura M. [1 ]
Beason-Held, Lori [2 ]
Tamminga, Carol A. [3 ]
Holcomb, Henry H. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat,Funct Neuroimaging Lab, Baltimore, MD 21228 USA
[2] NIA, Baltimore, MD 21224 USA
[3] Univ Texas SW Med Sch, Dept Psychiat, Dallas, TX USA
[4] Johns Hopkins Univ, Dept Psychiat, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
Nicotine; Glutamate; Dopamine; PET; NMDA receptor; Cingulate; Schizophrenia; Blood flow; Frontal cortex; RAT PREFRONTAL CORTEX; METHYL-D-ASPARTATE; EXCITATORY SYNAPTIC-TRANSMISSION; NMDA RECEPTOR ANTAGONIST; VENTRAL TEGMENTAL AREA; DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; INTRAVENOUS (H2O)-O-15; COGNITIVE DEFICITS; GLUTAMATE RELEASE;
D O I
10.1007/s00213-009-1758-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The purpose of this study was to determine if acute nicotine attenuated ketamine-induced regional cerebral blood flow (rCBF). Following 2-4 h of nicotine abstinence, healthy chronic smokers participated in four sets of rCBF studies, H (2) (15) O positron emission tomography, during a simple sensory motor control task. The four drug conditions studied were placebo, ketamine alone, nicotine alone, and ketamine + nicotine. Intravenous ketamine increased rCBF in frontal, orbital-frontal, and anterior cingulate areas. Nicotine alone induced marked rCBF elevations in the lateral occipital cortex and rCBF suppressions in the basal ganglia and anterior cingulate cortex. Nicotine added to ketamine attenuated the ketamine-induced elevated rCBF in the anterior cingulate cortex but caused a marked rCBF increase in the orbital frontal region. This study illustrates the interactive effects of ketamine, an NMDA receptor antagonist, and nicotine in multiple brain regions. Nicotine substantially ameliorated the effects of ketamine on anterior cingulate rCBF and, when given alone, markedly suppressed anterior cingulate rCBF. The enhanced, synergistic orbitofrontal effects observed with ketamine and nicotine together suggest a marked increase in excitatory neurotransmission in a brain region often linked to psychosis, reward, and addictive behaviors.
引用
收藏
页码:575 / 584
页数:10
相关论文
共 70 条
[1]   NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys [J].
Adams, BW ;
Bradberry, CW ;
Moghaddam, B .
SYNAPSE, 2002, 43 (01) :12-18
[2]   Dopaminergic modulation of local network activity in rat prefrontal cortex [J].
Bandyopadhyay, Susanta ;
Hablitz, John J. .
JOURNAL OF NEUROPHYSIOLOGY, 2007, 97 (06) :4120-4128
[3]  
Breier A, 1997, AM J PSYCHIAT, V154, P805
[4]   A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists [J].
Buccafusco, Jerry J. ;
Terry, Alvin V., Jr. .
BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) :852-862
[5]   Ionotropic Glutamate Receptors as Therapeutic Targets in Schizophrenia [J].
Coyle, Joseph T. ;
Tsai, Guochuan ;
Goff, Donald C. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (02) :183-189
[6]   Inhibitory gating of single unit activity in amygdala: Effects of ketamine, haloperidol, or nicotine [J].
Cromwell, Howard C. ;
Woodward, Donald J. .
BIOLOGICAL PSYCHIATRY, 2007, 61 (07) :880-889
[7]   Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings [J].
Dalack, GW ;
Healy, DJ ;
Meador-Woodruff, JH .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (11) :1490-1501
[8]   Nicotine and behavioral markers of risk for schizophrenia:: A double-blind, placebo-controlled, cross-over study [J].
Dépatie, L ;
O'Driscoll, GA ;
Holahan, ALV ;
Atkinson, V ;
Thavundayil, JX ;
Kin, NNY ;
Lal, S .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (06) :1056-1070
[9]   Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent [J].
Deutsch, SI ;
Rosse, RB ;
Billingslea, EN ;
Bellack, AS ;
Mastropaolo, J .
LIFE SCIENCES, 2003, 73 (18) :2355-2361
[10]  
Domino EF, 2000, SYNAPSE, V38, P313, DOI 10.1002/1098-2396(20001201)38:3<313::AID-SYN10>3.0.CO